Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Hexarelin
Examorelin, His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
GHRP-6
Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
A synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides known. Stimulates GH release more strongly than most other GHS peptides, but also has significant effects on cortisol and prolactin.
One of the original synthetic growth hormone secretagogues, developed in the 1980s. A hexapeptide that strongly stimulates GH release through ghrelin receptor activation. Historically significant as the compound that led to the discovery of the ghrelin receptor and the development of the entire GHS drug class.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering strong GH release. Also has direct cardioprotective effects independent of GH, including protection against ischemia-reperfusion injury. Activates the CD36 receptor in cardiac tissue.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release. Also stimulates appetite significantly through central ghrelin receptor activation — more so than most other GHS peptides. Increases IGF-1 levels downstream of GH release.
- Growth hormone optimization
- Muscle mass and strength
- Fat loss
- Cardiac protection (emerging research)
- Recovery from injury
- Growth hormone optimization
- Muscle recovery and growth
- Fat loss
- Appetite stimulation (useful in wasting conditions)
- Anti-aging protocols
- Significant cortisol and prolactin elevation (more than Ipamorelin)
- Water retention
- Increased appetite
- Desensitization with prolonged use
- Limited long-term human safety data
- Significant appetite stimulation (can undermine fat loss goals)
- Cortisol and prolactin elevation
- Water retention
- Desensitization with frequent dosing
- Tingling and numbness
- Limited long-term human safety data
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription. Often used in combination with GHRH analogs like CJC-1295.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.